#Germany #Veeva Systems #Boehringer Ingelheim #Ingelheim #One Medicine

Boehringer Ingelheim and Veeva Launch 'One Medicine Platform'

In a significant advancement for the pharmaceutical industry, Boehringer Ingelheim and Veeva Systems have officially launched the 'One Medicine Platform', marking a transformative step toward revolutionizing drug development and clinical trials. Announced on March 11, 2025, this partnership combines the powerful capabilities of Veeva’s Development Cloud with Boehringer’s innovative approach to healthcare solutions.

The roots of this collaboration stretch back to March 2022, when both companies recognized the need for a more integrated methodology in managing clinical trials, regulatory processes, and quality control. The 'One Medicine Platform' serves as a unified solution, designed to streamline and optimize various stages of product development within the pharmaceutical sector. With this platform, Boehringer aims to break down silos between departments, allowing for a more cohesive and efficient approach to drug creation.

Oliver Fink, head of learning, process, and digitalization at Boehringer Ingelheim, emphasized that this strategic partnership reaffirms their commitment to accelerating the delivery of groundbreaking treatments for patients worldwide. Fink stated, “Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world.” The 'One Medicine Platform' leverages extensive data handling capabilities to enhance collaboration with research sites, thus improving trial efficiency.

Veeva's Development Cloud offers a robust technological infrastructure enabling Boehringer to design and execute clinical studies with higher speed and compliance. By integrating clinical, regulatory, and quality data on the Veeva platform, both organizations aim for a seamless transition through the stages of drug development. Rik van Mol, senior vice president at Veeva, remarked on the platform's impact, asserting that it dismantles barriers across teams, fostering faster approvals and improved patient outcomes through informed decision-making.

This launch comes at a critical time, as the biopharma industry faces increasing pressure to deliver solutions for diseases that currently have no treatment. Boehringer and Veeva's collaborative efforts are expected to set a new standard in the life sciences field, illustrating how technology and data can reshape traditional processes. The One Medicine Platform represents a commitment to pushing the boundaries of research and addressing unmet medical needs.

Boehringer Ingelheim has a long-standing history in the biopharmaceutical industry, focusing on both human and animal health. Since its foundation in 1885, the company has positioned itself as a leading investor in research and development, underlining a commitment to sustainability and innovation. With over 53,500 employees serving more than 130 markets, Boehringer not only aspires to bring new medicines to the market but also aims to ensure a healthier and more sustainable future.

On the other hand, Veeva Systems stands as a front-runner in cloud-based software solutions tailored for the life sciences industry. With more than 1,000 customers, ranging from established pharmaceutical giants to emerging biotechs, Veeva exemplifies dedication to innovation and customer success. As a Public Benefit Corporation, Veeva focuses on balancing stakeholder interests and nourishing the industries it serves.

The unveiling of the 'One Medicine Platform' signals a promising future for pharmaceutical development, one that is driven by the need for speed, efficiency, and patient-centric care. This collaboration ultimately aims to reimagine clinical trials, ensuring that transformative therapies reach those in need more swiftly than ever before. With both companies committed to leveraging data and innovative solutions, the horizon for drug development looks brighter than ever before, standing as a beacon of hope for patients awaiting treatment for currently incurable diseases.

For additional information about Veeva's Development Cloud, visit veeva.com/DevelopmentCloud.

For more insights on Boehringer Ingelheim, explore boehringer-ingelheim.com.